Last 48 quarters of trend data · Healthcare · Medical - Devices
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -18.97 | — | 120.73 | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 1.71 | 1.66 | 1.15 | 1.22 | 1.35 | 2.05 | — | 2.35 | 3.06 | 2.30 | 1.93 | 1.64 | 2.15 |
| — | -19.3% | — | -48.2% | -56.0% | -10.9% | — | +43.1% | +42.0% | -17.0% | -29.4% | -23.8% | +5.1% | |
| P/B Ratio | 1.44 | 1.47 | 0.98 | 0.92 | 1.03 | 1.45 | 1.57 | 2.03 | 1.79 | 1.79 | 1.56 | 1.01 | 1.39 |
| — | +1.2% | -37.6% | -54.5% | -42.4% | -19.1% | +0.6% | +101.2% | +28.3% | +18.1% | +3.0% | -17.4% | +22.7% | |
| P/FCF | 44.30 | — | 8.83 | 6.80 | — | — | 220.28 | 28.50 | — | — | 46.15 | 11.87 | — |
| — | — | -96.0% | -76.1% | — | — | +377.3% | +140.1% | — | — | — | -86.1% | — | |
| EV / EBITDA | — | — | 13.71 | — | — | — | 1.79 | — | 343.88 | — | — | — | — |
| — | — | +664.1% | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | 41.67 | — | — | — | 2.15 | — | — | — | — | — | — |
| — | — | +1837.9% | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Anika Therapeutics, Inc.'s operating margin was -18.5% in Q1 2026, down 20.6 pp QoQ and down 2.2 pp YoY. The trailing four-quarter average of -10.7% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin expanded 14.3% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 56.6% | 64.2% | 62.6% | 56.0% | 50.9% | 56.1% | -1749.2% | 3.7% | 66.7% | 60.8% | 61.3% | 60.2% | 65.4% |
| — | +14.3% | +103.6% | +1407.7% | -23.7% | -7.7% | -2954.9% | -93.8% | +2.0% | +0.9% | +0.6% | +6.3% | +4.3% | |
| Operating Margin | -9.8% | -18.5% | 2.1% | -11.6% | -14.8% | -16.4% | -2156.4% | -72.3% | -5.9% | -12.5% | -148.4% | -18.5% | -8.2% |
| — | -13.2% | +100.1% | +83.9% | -151.4% | -31.0% | -1352.8% | -290.6% | +28.1% | +62.3% | -782.1% | -28.5% | +3.9% | |
| Net Margin | -9.6% | -17.1% | 1.0% | -8.4% | -14.1% | -18.6% | 1695.0% | -77.2% | -0.3% | -11.1% | -146.6% | -15.9% | -6.2% |
| — | +8.3% | -99.9% | +89.2% | -4812.2% | -67.2% | +1256.1% | -386.8% | +95.4% | +59.2% | -1083.6% | -52.9% | +13.7% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -7.3% | -3.6% | 0.2% | -1.6% | -2.7% | -3.2% | -13.1% | -15.3% | -0.0% | -2.1% | -26.1% | -2.4% | -1.0% |
| — | -13.1% | +101.5% | +89.7% | -6285.2% | -50.2% | +49.8% | -534.9% | +95.8% | +41.6% | -1416.9% | -65.2% | +0.0% | |
| ROA | -5.5% | -2.7% | 0.2% | -1.2% | -2.1% | -2.5% | -10.1% | -12.1% | -0.0% | -1.7% | -21.0% | -2.0% | -0.8% |
| — | -10.4% | +101.5% | +89.8% | -6184.1% | -46.7% | +52.1% | -505.0% | +95.9% | +43.8% | -1393.9% | -68.3% | -0.5% | |
| ROIC | -7.1% | -3.6% | 0.4% | -2.1% | -2.6% | -2.6% | 15.5% | -13.1% | -0.8% | -2.2% | -23.9% | -2.5% | -1.2% |
| — | -37.0% | -97.2% | +84.1% | -231.1% | -17.4% | +164.8% | -432.8% | +32.3% | +45.6% | -995.2% | -28.6% | -1.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
The current ratio has weakened 22.1% YoY to 4.46x, tightening the short-term liquidity position. Debt/Equity has risen for 3 consecutive quarters, indicating increasing financial leverage that investors should watch closely.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.17 | 0.19 | 0.17 | 0.17 | 0.17 | 0.17 | 0.17 | 0.15 | 0.13 | 0.14 | 0.13 | 0.11 | 0.11 |
| — | +12.1% | +0.1% | +9.1% | +26.8% | +25.5% | +28.9% | +41.3% | +22.5% | +24.7% | +20.8% | -0.7% | -1.3% | |
| Debt / EBITDA | — | — | 12.32 | — | — | — | 0.88 | — | 113.21 | — | — | — | — |
| — | — | +1307.7% | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 4.72 | 4.46 | 4.72 | 5.32 | 6.18 | 5.73 | 4.88 | 5.34 | 5.93 | 5.59 | 5.26 | 5.59 | 6.49 |
| — | -22.1% | -3.3% | -0.3% | +4.1% | +2.5% | -7.3% | -4.4% | -8.6% | -0.0% | -13.4% | -12.2% | +13.8% | |
| Quick Ratio | 3.86 | 3.37 | 3.86 | 4.47 | 5.12 | 4.53 | 3.85 | 3.78 | 3.96 | 3.85 | 4.47 | 4.03 | 4.67 |
| — | -25.6% | +0.1% | +18.1% | +29.3% | +17.8% | -13.8% | -6.1% | -15.2% | -7.2% | -3.8% | -18.7% | +3.8% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ANIK stock.
Anika Therapeutics, Inc.'s current P/E is -19.0x. The average P/E over the last 1 quarters is 120.7x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Anika Therapeutics, Inc.'s current operating margin is -9.8%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Anika Therapeutics, Inc.'s business trajectory between earnings reports.